Get started
Author

Philippe Rodon

Observed names: P Rodon, P. Rodon, Rodon, P., Rodon, Philippe
Observed institutions: Hôpital Necker-Enfants Malades, Inserm, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Hematology\Oncology Clinic, Centre Hospitalier de Béziers, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Régional et Universitaire de Nancy, Hôpital Saint-Antoine, Centre Hospitalier Universitaire de Reims, Institut de Cancérologie de l'Ouest, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Caen Normandie, CHU Dijon Bourgogne, Centre François Baclesse, Intergroupe Francophone du Myélome, Centre Hospitalier d'Arras, Groupe Francophone des Myélodysplasies, Hôpital Saint-Louis, Centre Hospitalier des Pays de Morlaix, Centre Hospitalier Universitaire de Rennes, Hôpital d'Hautepierre, Centre Henri Becquerel, Brest Business School
OpenAlex ID: A5042776012
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009 · Cyrille Hulin, Thierry Facon, et al. · Journal of Clinical Oncology · 381
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
2016 · Philippe Moreau, Cyrille Hulin, et al. · Blood · 278
PDF
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
2019 · Alemnew F Dagnew, Osman Ilhan, et al. · The Lancet Infectious Diseases · 256
Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma
2006 · T. Facon, J. Mary, et al. · Journal of Clinical Oncology · 194
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
2019 · Aurore Perrot, Valérie Lauwers-Cances, et al. · Journal of Clinical Oncology · 182
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
2015 · Marie-Lorraine Chretien, Jill Corre, et al. · Blood · 123
Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience
2013 · Hervé Avet-Loiseau, Cyrille Hulin, et al. · Journal of Clinical Oncology · 116
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
2021 · Thierry Facon, Christopher P. Venner, et al. · Blood · 103
PDF
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
2015 · Xavier Leleu, Lionel Karlin, et al. · Blood · 103
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
2016 · Cyrille Hulin, Andrew Belch, et al. · Journal of Clinical Oncology · 83
The Clinical Spectrum of IgM-Related Amyloidosis
2008 · Benjamin Terrier, Arnaud Jaccard, et al. · Medicine · 83
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
2012 · A. Palumbo, A. Waage, et al. · Haematologica · 74
PDF
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
2018 · Charles Dumontet, Cyrille Hulin, et al. · Leukemia · 73
PDF
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
2016 · Thomas Dejoie, Jill Corre, et al. · Blood · 72
Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.
2007 · Cyrille Hulin, Thierry Facon, et al. · Blood · 68
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
2019 · Brigitte Pegourie, Lionel Karlin, et al. · American Journal of Hematology · 61
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
2013 · Philippe Rodon, Cyrille Hulin, et al. · Thrombosis and Haemostasis · 60
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
2019 · Maroulio Pertesi, Maxime Vallée, et al. · Leukemia · 48
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
2006 · Jean-François Abgrall, Isabelle Guibaud, et al. · PubMed · 47
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
2011 · R. Houot, S. Le Gouill, et al. · Annals of Oncology · 44
Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath‐1H
2003 · Philippe Rodon, Philippe Breton, et al. · European Journal Of Haematology · 41
Multiple myeloma in elderly patients: presenting features and outcome
2001 · Philippe Rodon, Claude Linassier, et al. · European Journal Of Haematology · 40
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
2014 · P. Rodon, C. Hulin, et al. · Haematologica · 35
PDF
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study
2017 · Caroline Dartigeas, Eric Van Den Neste, et al. · The Lancet Haematology · 34
Works count: 95
Citation count: 3,003
H-index: 26
I10-index: 38
Year
Topic
Type